APA (7th ed.) Citation

Lin, J., Pearson, S., Greenfield, J. R., Park, K. H., Havard, A., Brieger, D., . . . de Oliveira Costa, J. (2023). Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022). European Journal of Clinical Pharmacology, 79(9), 1239. https://doi.org/10.1007/s00228-023-03539-8

Chicago Style (17th ed.) Citation

Lin, Jialing, Sallie-Anne Pearson, Jerry R. Greenfield, Kyeong Hye Park, Alys Havard, David Brieger, Richard O. Day, Michael O. Falster, and Juliana de Oliveira Costa. "Trends in Use of Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i) and Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) in Australia in the Era of Increased Evidence of Their Cardiovascular Benefits (2014–2022)." European Journal of Clinical Pharmacology 79, no. 9 (2023): 1239. https://doi.org/10.1007/s00228-023-03539-8.

MLA (9th ed.) Citation

Lin, Jialing, et al. "Trends in Use of Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i) and Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) in Australia in the Era of Increased Evidence of Their Cardiovascular Benefits (2014–2022)." European Journal of Clinical Pharmacology, vol. 79, no. 9, 2023, p. 1239, https://doi.org/10.1007/s00228-023-03539-8.